Katarzyna Borg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katarzyna Borg has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Krzysztof Warzocha
Klinika Hematologii, Instytut Hematologii i Transfuzjologii, ul. Indiry Gandhi 14, 02–776 Warszawa, Polska
9 shared publications - Iwona Solarska
Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
7 shared publications - Przemyslaw Juszczynski
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
6 shared publications - Ewa Lech-Maranda
Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland
5 shared publications - Monika Prochorec-Sobieszek
Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland
5 shared publications - Barbara Nasilowska-Adamska
Department of Hematopoietic Stem Cell Transplantation, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
4 shared publications
Latest Publications
- Open Access
Prognostic Impact of Copy Number Alterations’ Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy
Adult acute lymphoblastic leukemia (ALL) is associated with poor outcomes. ALL is initiated by primary aberrations, but secondary genetic lesions are necessary for overt ALL. In this study, we reassessed the value of primary and secondary aberrations in intensively treated ALL patients in relation to mutator enzyme expression. RT-PCR, genomic PCR, and sequencing were applied to evaluate primary aberrations, while qPCR was used to measure the expression of RAG and AID mutator enzymes in 166 adult ALL patients. Secondary copy number alterations (CNA) were studied in 94 cases by MLPA assay. Primary aberrations alone stratified 30% of the patients (27% high-risk, 3% low-risk cases). The remaining 70% intermediate-risk patients included BCR::ABL1pos subgroup and ALL lacking identified genetic markers (NEG ALL). We identified three CNA profiles: high-risk bad-CNA (CNAhigh/IKZF1pos), low-risk good-CNA (all other CNAs), and intermediate-risk CNAneg. Furthermore, based on RAG/AID expression, we report possible mechanisms underlying the CNA profiles associated with poor outcome: AID stratified outcome in CNAneg, which accompanied most likely a particular profile of single nucleotide variations, while RAG in CNApos increased the odds for CNAhigh/IKZF1pos development. Finally, we integrated primary genetic aberrations with CNA to propose a revised risk stratification code, which allowed us to stratify 75% of BCR::ABL1pos and NEG patients.
Open AccessPrognostic Impact of Copy Number Alterations’ Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy
Adult acute lymphoblastic leukemia (ALL) is associated with poor outcomes. ALL is initiated by primary aberrations, but secondary genetic lesions are necessary for overt ALL. In this study, we reassessed the value of primary and secondary aberrations in intensively treated ALL patients in relation to mutator enzyme expression. RT-PCR, genomic PCR, and sequencing were applied to evaluate primary aberrations, while qPCR was used to measure the expression of RAG and AID mutator enzymes in 166 adult ALL patients. Secondary copy number alterations (CNA) were studied in 94 cases by MLPA assay. Primary aberrations alone stratified 30% of the patients (27% high-risk, 3% low-risk cases). The remaining 70% intermediate-risk patients included BCR::ABL1pos subgroup and ALL lacking identified genetic markers (NEG ALL). We identified three CNA profiles: high-risk bad-CNA (CNAhigh/IKZF1pos), low-risk good-CNA (all other CNAs), and intermediate-risk CNAneg. Furthermore, based on RAG/AID expression, we report possible mechanisms underlying the CNA profiles associated with poor outcome: AID stratified outcome in CNAneg, which accompanied most likely a particular profile of single nucleotide variations, while RAG in CNApos increased the odds for CNAhigh/IKZF1pos development. Finally, we integrated primary genetic aberrations with CNA to propose a revised risk stratification code, which allowed us to stratify 75% of BCR::ABL1pos and NEG patients.
- Open Access
- 12 July 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (7) , 1674
Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing
Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four different patterns of mutation evolution were found: branching-, mutation acquisition-, mutation loss- and a stable mutational pathway. Better response to anti-myeloma therapy was more frequently observed in patients who followed the mutation loss—compared to the mutation acquisition pathway. More than two-thirds of patients had druggable genes mutated (including cases of heavily pre-treated disease). Only 7% of patients had a stable copy number variants profile. Consequently, a redistribution in stages according to R-ISS between the first and paired samples (R-ISS″) was seen. The higher the R-ISS″, the higher the risk of MM progression and death. We provided new insights into the genetics of MM evolution, especially in heavily pre-treated patients. Additionally, we confirmed that redefining R-ISS at MM relapse is of high clinical value.
- 12 July 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (7) , 1674
Open AccessTracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing
Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four different patterns of mutation evolution were found: branching-, mutation acquisition-, mutation loss- and a stable mutational pathway. Better response to anti-myeloma therapy was more frequently observed in patients who followed the mutation loss—compared to the mutation acquisition pathway. More than two-thirds of patients had druggable genes mutated (including cases of heavily pre-treated disease). Only 7% of patients had a stable copy number variants profile. Consequently, a redistribution in stages according to R-ISS between the first and paired samples (R-ISS″) was seen. The higher the R-ISS″, the higher the risk of MM progression and death. We provided new insights into the genetics of MM evolution, especially in heavily pre-treated patients. Additionally, we confirmed that redefining R-ISS at MM relapse is of high clinical value.
- Open Access
- 7 May 2018
- Published by Termedia Sp. z.o.o. in Polish Journal of Pathology
- Vol. 69 (1) , 1-19
Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation’s 2017 classification
Revision of the fourth edition of the World Health Organisation (WHO) Classification of Haematopoietic and Lymphatic Tissues, which was published in 2017, introduced important changes updating the biology, pathology, genetics, and clinical presentation of aggressive B-cell lymphomas. High grade B-cell lymphomas (HGBLs) replaced B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, the new provisional entity Burkitt-like lymphoma with 11q aberration was identified, and some categories were upgraded, e.g. EBV-positive diffuse large B-cell lymphoma, not otherwise specified. Still the histopathological diagnostics is based on morphology and immunoprofile, but to define the HGBLs evaluation of MYC, BCL2, and BCL6 gene statuses is required. According to the presented WHO criteria, in the comprehensive histopathological diagnostics of aggressive B-cell lymphomas a highly specialised diagnostic team including a pathologist, a molecular biologist, a geneticist, a haematologist, and immunophenotyping technicians is needed.
- 7 May 2018
- Published by Termedia Sp. z.o.o. in Polish Journal of Pathology
- Vol. 69 (1) , 1-19
Open AccessComprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation’s 2017 classification
Revision of the fourth edition of the World Health Organisation (WHO) Classification of Haematopoietic and Lymphatic Tissues, which was published in 2017, introduced important changes updating the biology, pathology, genetics, and clinical presentation of aggressive B-cell lymphomas. High grade B-cell lymphomas (HGBLs) replaced B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, the new provisional entity Burkitt-like lymphoma with 11q aberration was identified, and some categories were upgraded, e.g. EBV-positive diffuse large B-cell lymphoma, not otherwise specified. Still the histopathological diagnostics is based on morphology and immunoprofile, but to define the HGBLs evaluation of MYC, BCL2, and BCL6 gene statuses is required. According to the presented WHO criteria, in the comprehensive histopathological diagnostics of aggressive B-cell lymphomas a highly specialised diagnostic team including a pathologist, a molecular biologist, a geneticist, a haematologist, and immunophenotyping technicians is needed.
- Open Access
- 17 April 2018
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (7) , 3548-3559
Microenvironment‐induced PIM kinases promote CXCR4‐triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration
Lymph node microenvironment provides chronic lymphocytic leukaemia (CLL) cells with signals promoting their survival and granting resistance to chemotherapeutics. CLL cells overexpress PIM kinases, which regulate apoptosis, cell cycle and migration. We demonstrate that BCR crosslinking, CD40 stimulation, and coculture with stromal cells increases PIMs expression in CLL cells, indicating microenvironment‐dependent PIMs regulation. PIM1 and PIM2 expression at diagnosis was higher in patients with advanced disease (Binet C vs. Binet A/B) and in those, who progressed after first‐line treatment. In primary CLL cells, inhibition of PIM kinases with a pan‐PIM inhibitor, SEL24‐B489, decreased PIM‐specific substrate phosphorylation and induced dose‐dependent apoptosis in leukaemic, but not in normal B cells. Cytotoxicity of SEL24‐B489 was similar in TP53‐mutant and TP53 wild‐type cells. Finally, inhibition of PIM kinases decreased CXCR4‐mediated cell chemotaxis in two related mechanisms‐by decreasing CXCR4 phosphorylation and surface expression, and by limiting CXCR4‐triggered mTOR pathway activity. Importantly, PIM and mTOR inhibitors similarly impaired migration, indicating that CXCL12‐triggered mTOR is required for CLL cell chemotaxis. Given the microenvironment‐modulated PIM expression, their pro‐survival function and a role of PIMs in CXCR4‐induced migration, inhibition of these kinases might override microenvironmental protection and be an attractive therapeutic strategy in this disease.
- 17 April 2018
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (7) , 3548-3559
Open AccessMicroenvironment‐induced PIM kinases promote CXCR4‐triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration
Lymph node microenvironment provides chronic lymphocytic leukaemia (CLL) cells with signals promoting their survival and granting resistance to chemotherapeutics. CLL cells overexpress PIM kinases, which regulate apoptosis, cell cycle and migration. We demonstrate that BCR crosslinking, CD40 stimulation, and coculture with stromal cells increases PIMs expression in CLL cells, indicating microenvironment‐dependent PIMs regulation. PIM1 and PIM2 expression at diagnosis was higher in patients with advanced disease (Binet C vs. Binet A/B) and in those, who progressed after first‐line treatment. In primary CLL cells, inhibition of PIM kinases with a pan‐PIM inhibitor, SEL24‐B489, decreased PIM‐specific substrate phosphorylation and induced dose‐dependent apoptosis in leukaemic, but not in normal B cells. Cytotoxicity of SEL24‐B489 was similar in TP53‐mutant and TP53 wild‐type cells. Finally, inhibition of PIM kinases decreased CXCR4‐mediated cell chemotaxis in two related mechanisms‐by decreasing CXCR4 phosphorylation and surface expression, and by limiting CXCR4‐triggered mTOR pathway activity. Importantly, PIM and mTOR inhibitors similarly impaired migration, indicating that CXCL12‐triggered mTOR is required for CLL cell chemotaxis. Given the microenvironment‐modulated PIM expression, their pro‐survival function and a role of PIMs in CXCR4‐induced migration, inhibition of these kinases might override microenvironmental protection and be an attractive therapeutic strategy in this disease.
- 1 October 2017
- Published by Walter de Gruyter GmbH in Acta Haematologica Polonica
- Vol. 48 (4) , 343-349
Genomic landscape of human erythroleukemia K562 cell line, as determined by next-generation sequencing and cytogenetics
- 1 October 2017
- Published by Walter de Gruyter GmbH in Acta Haematologica Polonica
- Vol. 48 (4) , 343-349
Genomic landscape of human erythroleukemia K562 cell line, as determined by next-generation sequencing and cytogenetics
- 15 June 2017
- Published by Wiley in European Journal of Haematology
- Vol. 99 (3) , 255-261
BCRP mRNA and FLT3‐ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype
Purpose: FMS‐like tyrosine kinase 3‐internal tandem duplication (FLT3‐ITD) is aberration associated with poor prognosis in AML. We have analyzed the expression of MDR‐1, MRP‐1, and BCRP mRNA in relation to FLT3‐ITD in 100 AML adult patients with normal and intermediate karyotype.Methods: The RQ‐PCR method was performed to assess the expression of MDR‐1, MRP‐1, and BCRP mRNA, and the results were presented as coefficients calculated using an intermediate method according to Pfaffl's rule.Results: According to univariate analysis, the following pretreatment variables negatively influenced disease‐free survival (DFS): WBC count ≥25×109/L (P=.037), MRP‐1 mRNA ≥1.6818 (P=.028), BCRP mRNA ≥1.1892 (P=.004), FLT3‐ITD (P=.005) and overall survival (OS): WBC count ≥25×109/L (P=.031), MRP‐1 mRNA ≥1.6818 (P=.01), BCRP mRNA ≥1.1892 (P=.01), FLT3‐ITD (P=.001). When all prognostic variables were pooled into a multivariate model, we found that WBC count ≥25×109/L (P=.026) and BCRP mRNA ≥1.1892 (P=.011). We observed trend in negative influence of FLT3‐ITD on DFS (P=.057). BCRP mRNA ≥1.1892 (P=.035) and FLT3‐ITD (P=.006) negatively, independently influenced the OS.Conclusions: The high expressions of BCRP mRNA calculated with Pfaffl's rule and FLT3‐ITD are independent poor risk factors in adult patients with AML and intermediate or normal karyotype.
- 15 June 2017
- Published by Wiley in European Journal of Haematology
- Vol. 99 (3) , 255-261
BCRP mRNA and FLT3‐ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype
Purpose: FMS‐like tyrosine kinase 3‐internal tandem duplication (FLT3‐ITD) is aberration associated with poor prognosis in AML. We have analyzed the expression of MDR‐1, MRP‐1, and BCRP mRNA in relation to FLT3‐ITD in 100 AML adult patients with normal and intermediate karyotype.Methods: The RQ‐PCR method was performed to assess the expression of MDR‐1, MRP‐1, and BCRP mRNA, and the results were presented as coefficients calculated using an intermediate method according to Pfaffl's rule.Results: According to univariate analysis, the following pretreatment variables negatively influenced disease‐free survival (DFS): WBC count ≥25×109/L (P=.037), MRP‐1 mRNA ≥1.6818 (P=.028), BCRP mRNA ≥1.1892 (P=.004), FLT3‐ITD (P=.005) and overall survival (OS): WBC count ≥25×109/L (P=.031), MRP‐1 mRNA ≥1.6818 (P=.01), BCRP mRNA ≥1.1892 (P=.01), FLT3‐ITD (P=.001). When all prognostic variables were pooled into a multivariate model, we found that WBC count ≥25×109/L (P=.026) and BCRP mRNA ≥1.1892 (P=.011). We observed trend in negative influence of FLT3‐ITD on DFS (P=.057). BCRP mRNA ≥1.1892 (P=.035) and FLT3‐ITD (P=.006) negatively, independently influenced the OS.Conclusions: The high expressions of BCRP mRNA calculated with Pfaffl's rule and FLT3‐ITD are independent poor risk factors in adult patients with AML and intermediate or normal karyotype.
- 21 January 2016
- Published by American Society of Hematology in Blood
- Vol. 127 (3) , 360-362
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients
- 21 January 2016
- Published by American Society of Hematology in Blood
- Vol. 127 (3) , 360-362
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients
- 1 December 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 55 (4) , 284-292
CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis
- 1 December 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 55 (4) , 284-292
CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis
- 16 November 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (6) , 1471-1473
Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease
Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease.. . . doi: 10.3109/10428194.2015.1096355
- 16 November 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (6) , 1471-1473
Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease
Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease.. . . doi: 10.3109/10428194.2015.1096355
- 27 April 2015
- Published by Wiley in European Journal of Haematology
- Vol. 96 (3) , 236-244
Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remissio
- 27 April 2015
- Published by Wiley in European Journal of Haematology
- Vol. 96 (3) , 236-244
Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remissio